Lewy Body Dementia (LBD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Summary
This reports provides a data-driven overview of the current and future competitive landscape in LBD therapeutics.
There will be more than 1.1 million diagnosed prevalent cases of LBD in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast.
Currently, there are three marketed products for the treatment of LBD.
R&D activity within the LBD space is negligible, with no pipeline products in late-stage clinical development.
Commercial sponsors dominate clinical trial development in LBD, with the US and the UK emerging as the key countries for conducting trials in this disease space.
Deals involving partnerships were the most common type of deals globally involving companies developing LBD assets.
Scope
GlobalData’s LBD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the LBD market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global LBD market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Findings
Disease Overview
Epidemiology Overview
Epidemiology Overview: Diagnosed Prevalent Cases of LBD in 2023 and 2028
Treatment Overview
Treatment Guidelines
Marketed Drugs Assessment
Marketed Drugs – Leading Marketed Drugs in LBD
Marketed Drugs – Overview by Mechanism of Action
Marketed Drug Profile: Sumitomo Pharma’s Trerief
Marketed Drug Profile: Eisai’s Aricept
Marketed Drug Profile: Instituto Vital’s Rivastigmine Hemitartrate
Pricing and Reimbursement Assessment
Marketed Drugs – Manufacturer Price for Oral Formulations for LBD
Pipeline Drugs Assessment
Pipeline Drugs Overview – Mid-to-Late-Stage Pipeline Drugs in LBD
Pipeline Drugs – Overview by Development Stage
Pipeline Drugs – Overview by Mechanism of Action
Pipeline Drugs – Overview by Route of Administration
Pipeline Drugs – Overview by Molecule Type
Pipeline Drugs – PTSRs and LoAs in CNS
Clinical Trials Assessment
Clinical Trials in LBD – Historical Overview
Clinical Trials in LBD – Overview by Phase
Clinical Trials in LBD – Overview by Status
Clinical Trials in LBD – Overview by Phase for Ongoing and Planned Trials
Clinical Trials in LBD – Trials with a Virtual Component
Clinical Trials in LBD – Geographic Overview
Clinical Trials in LBD – Single-Country and Multinational Trials by Region
Clinical Trials in LBD – Top 20 Sponsors with Breakdown by Phase
Clinical Trials in LBD – Top 20 Sponsors with Breakdown by Status
Clinical Trials in LBD – Overview by Endpoint Status
Clinical Trials in LBD – Overview by Race
Clinical Trials in LBD – Enrollment Data
Clinical Trials in LBD – Overview of Sites by Geography
Clinical Trials in LBD – Top 20 Countries for Trial Sites